Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2014

01-06-2014 | Original Article

Overestimation of the risk of progression to end-stage renal disease in the poor prognosis’ group according to the 2002 Japanese histological classification for immunoglobulin A nephropathy

Authors: Yoichi Miyazaki, Tetsuya Kawamura, Kensuke Joh, Hideo Okonogi, Kentaro Koike, Yasunori Utsunomiya, Makoto Ogura, Masato Matsushima, Mitsuhiro Yoshimura, Satoshi Horikoshi, Yusuke Suzuki, Akira Furusu, Takashi Yasuda, Sayuri Shirai, Takanori Shibata, Masayuki Endoh, Motoshi Hattori, Yuko Akioka, Ritsuko Katafuti, Akinori Hashiguchi, Kenjiro Kimura, Seiichi Matsuo, Yasuhiko Tomino

Published in: Clinical and Experimental Nephrology | Issue 3/2014

Login to get access

Abstract

Background

The current (2012) histological classification of immunoglobulin A nephropathy was established using a case–control study of 287 patients. However, the risk of progression to end-stage renal disease (ESRD) has not been validated for the previous (2002) classification. This study aimed to determine whether the previous classification could identify the risk of long-term renal outcome through re-analysis of the 2012 cohort.

Methods

On the basis of the 2002 classification, namely ‘good prognosis’, ‘relatively good prognosis’, ‘relatively poor prognosis’, and ‘poor prognosis’, we examined the clinical data at the time of biopsy, the correlation between the 2002 classification and long-term renal outcomes, and a patient-by-patient correlation between the 2002 and 2012 classification systems. This was performed by analyzing samples from the 287 patients used to establish the 2012 classification.

Results

The rate of decline of estimated glomerular filtration rate was greater and the odds ratio of progression to ESRD was higher in the ‘poor prognosis’ group. In contrast, the odds ratio for renal death was comparable between the groups described as ‘relatively poor prognosis’ and ‘relatively good prognosis’ in the 2002 classification. Many patients in the 2002 classification were classified with a lower histological grade in the current classification, but none were classified with a higher grade.

Conclusions

The 2002 classification could also identify the risk of progression to ESRD. However, it was overestimated for patients in the ‘poor prognosis’ group in the 2002 classification, as that group included patients with milder histological damage.
Literature
1.
go back to reference Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Miyazaki Y, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol. 2012;26:350–7.PubMedCrossRef Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Miyazaki Y, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol. 2012;26:350–7.PubMedCrossRef
2.
go back to reference Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Katz AI. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13:314–22.PubMedCrossRef Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Katz AI. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13:314–22.PubMedCrossRef
3.
go back to reference Lee HS, Koh HI, Lee HB, Park HC. IgA nephropathy in Korea: a morphological and clinical study. Clin Nephrol. 1987;27:131–40.PubMed Lee HS, Koh HI, Lee HB, Park HC. IgA nephropathy in Korea: a morphological and clinical study. Clin Nephrol. 1987;27:131–40.PubMed
4.
go back to reference Johnston PA, Brown JS, Braumholz DA, Davison AM. Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy: a report from MRC Glomerulonephritis Registry. Q J Med. 1992;84:619–27.PubMed Johnston PA, Brown JS, Braumholz DA, Davison AM. Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy: a report from MRC Glomerulonephritis Registry. Q J Med. 1992;84:619–27.PubMed
5.
go back to reference Haas M. Histologic subclassification of IgA nephropathy: a cliniclpathologic study of 244 cases. Am J Kidney Dis. 1997;29:829–42.PubMedCrossRef Haas M. Histologic subclassification of IgA nephropathy: a cliniclpathologic study of 244 cases. Am J Kidney Dis. 1997;29:829–42.PubMedCrossRef
6.
go back to reference Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant. 2005;20:342–8.PubMedCrossRef Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant. 2005;20:342–8.PubMedCrossRef
7.
go back to reference Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006;21:2800–8.PubMedCrossRef Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006;21:2800–8.PubMedCrossRef
8.
go back to reference Manno C, Strippoli GF, D’Altri C, Torres D, Rossini M, Schena FP. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007;49:763–75.PubMedCrossRef Manno C, Strippoli GF, D’Altri C, Torres D, Rossini M, Schena FP. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007;49:763–75.PubMedCrossRef
9.
go back to reference Tomino Y, Sakai H. Special Study Group (IgA Nephropathy) on Progressive Glomerular Disease. Clinical guideline for immunoglobulin A (IgA) nephropathy in Japan, 2nd version. Clin Exp Nephrol. 2003;7:93–7.PubMedCrossRef Tomino Y, Sakai H. Special Study Group (IgA Nephropathy) on Progressive Glomerular Disease. Clinical guideline for immunoglobulin A (IgA) nephropathy in Japan, 2nd version. Clin Exp Nephrol. 2003;7:93–7.PubMedCrossRef
10.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef
11.
go back to reference Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Robert IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: Pathology definitions, correlations and reproducibility. Kidney Int. 2009;76:546–56.CrossRef Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Robert IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: Pathology definitions, correlations and reproducibility. Kidney Int. 2009;76:546–56.CrossRef
12.
go back to reference Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classification of IgA nephrolaty: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76:534–45. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classification of IgA nephrolaty: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76:534–45.
13.
go back to reference Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef
14.
go back to reference Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–7.PubMedCrossRef Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–7.PubMedCrossRef
15.
go back to reference Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedCentralPubMedCrossRef Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedCentralPubMedCrossRef
16.
go back to reference Hirano K, Kawamura T, Tsuboi N, Okonogi H, Miyazaki Y, Ikeda M et al. The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol (in press). Hirano K, Kawamura T, Tsuboi N, Okonogi H, Miyazaki Y, Ikeda M et al. The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol (in press).
17.
go back to reference Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.PubMedCrossRef Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.PubMedCrossRef
18.
go back to reference Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, et al. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. (in press). Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, et al. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. (in press).
Metadata
Title
Overestimation of the risk of progression to end-stage renal disease in the poor prognosis’ group according to the 2002 Japanese histological classification for immunoglobulin A nephropathy
Authors
Yoichi Miyazaki
Tetsuya Kawamura
Kensuke Joh
Hideo Okonogi
Kentaro Koike
Yasunori Utsunomiya
Makoto Ogura
Masato Matsushima
Mitsuhiro Yoshimura
Satoshi Horikoshi
Yusuke Suzuki
Akira Furusu
Takashi Yasuda
Sayuri Shirai
Takanori Shibata
Masayuki Endoh
Motoshi Hattori
Yuko Akioka
Ritsuko Katafuti
Akinori Hashiguchi
Kenjiro Kimura
Seiichi Matsuo
Yasuhiko Tomino
Publication date
01-06-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0848-y

Other articles of this Issue 3/2014

Clinical and Experimental Nephrology 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine